Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Allergan Purchases Drug Developer

by Michael McCoy
January 28, 2013 | A version of this story appeared in Volume 91, Issue 4

Allergan will acquire MAP Pharmaceuticals in an all-cash transaction valued at $958 million. Originally an eye care firm, Allergan has expanded into businesses such as obesity intervention, breast enhancement, and Botox, which is both a wrinkle reducer and a treatment for chronic migraine. MAP recently submitted a New Drug Application for Levadex, an inhaled version of the migraine treatment dihydroergotamine. Allergan CEO David E. I. Pyott says his firm also plans to use MAP’s drug particle and inhalation technologies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.